Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      

This page is updated frequently with new Mammal-related patent applications.




Date/App# patent app List of recent Mammal-related patents
04/07/16
20160097768 
 Polyvalent chimeric ospc vaccinogen and diagnostic antigen patent thumbnailPolyvalent chimeric ospc vaccinogen and diagnostic antigen
Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for lyme disease (e.g. In canines and humans) are provided.
Virginia Commonwealth University


04/07/16
20160097081 
 Internalization of proteins into hollowed gold nanostructures patent thumbnailInternalization of proteins into hollowed gold nanostructures
Provided is a gold nanocage with pores, charged ligand molecules covalently bound to internal surfaces of the gold nanocage, and payload molecules electrostatically adsorbed onto said charged ligand molecules, wherein a pore diameter is between 1.2 and 20 times a gyration radius of the payload molecule. Also provided is a method for making a nanoparticle, including using polyvinylpyrrolidone as a capping agent in a galvanic replacement reaction to convert a silver nanocube into a gold nanocage having pores, replacing the polyvinylpyrrolidone on internal surfaces with charged ligand molecules, and electrostatically adsorbing payload molecules onto the charged ligand molecules, with a pore diameter less than twenty times a gyration radius of the payload molecule.
Rensselaer Polytechnic Institute


04/07/16
20160096875 
 Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells patent thumbnailCodon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160096861 
 Novel galactoside inhibitor of galectins patent thumbnailNovel galactoside inhibitor of galectins
The compound of formula (i) is suitable for treating pulmonary fibrosis, such as idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound..

04/07/16
20160096855 
 Method of treating colorectal cancer patent thumbnailMethod of treating colorectal cancer
The present invention relates to the use of certain platinum compounds including [ptcb(cis-1,4-diaminocyclohexane)], or combinations of these compounds with a variety of other agents for treating and/or preventing the progression of colorectal cancer in mammals. In particular, the invention provides methods of treating and/or preventing oxaliplatin-refractory colorectal cancer in mammals..

04/07/16
20160096818 
 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and  reducing tnfalpha levels patent thumbnailSubstituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and reducing tnfalpha levels
Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of tnfα in a mammal..
Celgene Corporation


04/07/16
20160095938 
 Conjugates comprising cell-binding agents and cytotoxic agents patent thumbnailConjugates comprising cell-binding agents and cytotoxic agents
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (cba) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the cba. The invention also provides methods of preparing the conjugates of the present invention.
Immunogen, Inc.


04/07/16
20160095921 
 Combinations and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies patent thumbnailCombinations and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (ibd) such as crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with ibd a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (ccr9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab.
Chemocentryx, Inc.


04/07/16
20160095916 
 Induction of cross-reactive cellular response against rhinovirus antigens patent thumbnailInduction of cross-reactive cellular response against rhinovirus antigens
The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the vp4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 c-terminal amino acids of the rna polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.. .
Imperial Innovations Limited


04/07/16
20160095910 
 Self-assembling synthetic proteins patent thumbnailSelf-assembling synthetic proteins
The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host..

04/07/16
20160095893 

Plant-derived formulations for treatment of hiv


Disclosed herein are methods for treating mammals with hiv/aids comprising administering a therapeutically effective amount of a composition comprising an extract of rubia cordifolia. The extract is preferably an alcohol extract, an aqueous extract, or mixtures thereof.
The Florida International University Board Of Trustees


04/07/16
20160095892 

Sour cherry topical biotherapeutic formulations, manufacture and treatment of human osteoarthritis symptoms


A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by cd3+ t lymphocytes in a vertebrate mammal.. .

04/07/16
20160095881 

Promoting muscle building and repair and treating disorders related to collagen and pertinent proteins by using shilajit


A method of using shilajit or its individual components, or a combination of two or more of these components, to induce the body of a mammal, including that of a human, to synthesize new collagen and the related extracellular matrix proteins, thus promoting the health of all of the tissues and organs containing collagen and the related extracellular matrix proteins, including skin, connective tissue, muscle, cartilage, bone, and teeth and improve muscle building and regeneration, and/or treat collagen-related disorders is presented.. .
Natreon, Inc.


04/07/16
20160095864 

Composition for reducing cell senescence comprising rho-kinase inhibitor and use thereof


A composition for reducing cell senescence including a rho-kinase inhibitor and method of treating a cell senescence-related symptom in mammals.. .
Samsung Electronics Co., Ltd.


04/07/16
20160095711 

Spacer for spinal implant


The present invention is a spinal implant that can be inserted into a surgically created cavity of one or more regions of the mammalian spine. Among other things, the biocompatible implant and end cap or biocompatible implant, end cap and spacer combinations can assist with the restoration of the normal anatomic spinal alignment and spinal stability..
Igip, Llc


04/07/16
20160095343 

Synbiotic product


The present invention relates to a synbiotic product composition comprising a blend or mixture of a prebiotic carbohydrate and a probiotic spore-forming bacillus bacteria. Examples of prebiotic carbohydrates useful in synbiotic product include arabinoxylan, arabinoxylan oligosaccharides, xylose, soluble fiber dextrin, soluble corn fiber, and polydextrose.
Tate & Lyle Ingredients Americas Llc


04/07/16
20160095320 

Mixture to increase the effectiveness of antiseptics and/or disinfectants, an agent containing the mixture, and the use of this mixture


The invention relates to the increase (improvement) of the effectiveness of antiseptics and/or disinfectants administered in a mixture with hydrolytic or proteolytic enzymes to a mucous membrane, a skin of a mammal or inanimate surfaces in the form of a solution, gel, paste, capsules or other as an agent. The use of the mixture is also stated..
Wald Pharmaceuticals S.r.o.


03/31/16
20160090637 

Pharmacogenomic biomarkers for b cell malignancies and methods of use thereof


The present invention relates to diagnosing drug-resistant chronic lymphocytic leukemia (cll) in a mammal.. .

03/31/16
20160090574 

A process for the production of adenovirus


The present disclosure relates to a process for the manufacture of adenoviruses wherein the process comprises culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and at the end of the culturing period isolating from the media the adenovirus by filtering wherein the isolation of virus is not subsequent to a cell lysis step and to viruses obtainable from the process.. .
Psioxus Therapuetics Limited


03/31/16
20160089477 

Porous foams derived from extracellular matrix, porous foam ecm medical devices, and methods of use and making thereof


The invention disclosed herein is directed to a porous wound healing foam composition that is made from an extracellular matrix of a mammal, method of making, and method of using.. .
Acell, Inc.


03/31/16
20160089418 

Therapeutic compositions for neutralizing type i interferons, and methods of use


The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing type i interferons in a mammal. The compositions contain a soluble orthopoxvirus ifn-binding protein that is modified to remove the cell-binding region, and that specifically binds to type i ifns, and a pharmaceutically acceptable carrier or excipient.
The United States Of America As Represented By The Secretary Of The Army, Of Behalf Of The United


03/31/16
20160089363 

Compositions and methods for treating microbiota-related psychotropic conditions and diseases


In alternative embodiments, the invention provides compositions and methods for treating, ameliorating and preventing various disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor, for example, where the microbial or bacterial flora of the bowel manufactures neurotoxins or neurotoxic agents that enter the body through the gastrointestinal (gi) tract, e.g. The colon, and reach the systemic space, e.g., by neural streaming or via the circulation, to reach the central nervous system (cns), including the brain, the peripheral nervous system (pns), and other nervous systems.

03/31/16
20160089340 

Composition comprising farnesol and use thereof


A method of increasing pgc-1α gene expression, decreasing paris gene expression, or promoting farnesylation of paris in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions.. .
Research & Business Foundation Sungkyunkwan University


03/31/16
20160089329 

Extended release of neuregulin for treating heart failure


The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump..
Zensun (shanghai) Science & Technology, Ltd


03/31/16
20160089062 

Method and a mobile app for use with a mobile device to accurately quantify blood hemoglobin in mammals


A method and a mobile app are disclosed for obtaining hemoglobin count in the blood of a mammal using digital images of the conjunctiva of the eye of the mammal taken with a camera of a mobile device running the mobile app. The mobile app carries out a method including: obtaining a color image of the conjunctiva of the eye using the digital camera; computing an r/b ratio and a y/i ratio of the color image; normalizing the r/b ratio and the y/i ratio using color image normalization parameters obtained using a master camera so as to provide a r/b true ratio and a y/i true ratio; and using the r/b true ratio and the y/i true ratio as inputs to respective look-up tables created using the master camera so as to provide an accurate measure of blood hemoglobin count..

03/24/16
20160084853 

Biomarkers for age-related macular degeneration (amd)


The present application is directed to the use of a vegf-c inhibitor, a vegfr-2 inhibitor and/or a vegfr-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a vegf-c measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization..

03/24/16
20160084844 

Methods of identifying glycopeptides recognized by disease-associated auto-antibodies


Methods for identifying glycopeptides and more particularly glycopeptide epitopes that are specifically recognized by disease-associated auto-antibodies are provided. In some aspects the auto-antibodies are cancer-associated or autoimmune disease associated.
Glycozym, Inc.


03/24/16
20160083803 

Methods and materials for detecting colorectal neoplasm


The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human dna, tumor assoicated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal..
Mayo Foundation For Medical Education And Research


03/24/16
20160083747 

Intracellular translation of circular rna


A circular mrna molecule possessing features resembling native mammalian mrna demonstrates improved translation, while retaining the properties of an extremely long half-life inside cells. This circular mrna is functional inside mammalian cells, being able to compete against native cellular mrnas for the eukaryotic translation initiation machinery.
Ribokine Llc


03/24/16
20160083733 

Novel treatment of metabolic diseases


Antagonists of mammalian sterile 20-like kinase (mst) 1 for use in the treatment and prevention of metabolic diseases, in particular diabetes and obesity are described.. .
University Of Bremen


03/24/16
20160083699 

High efficiency flp site-specific recombination in mammalian cells using an optimized flp gene


The present invention provides an optimized flp site-specific recombinase coding sequence and methods for its use. This genetically engineered flp gene displays a marked increase in recombination efficiency compared to the native flp gene and is therefore useful in a wide array of molecular applications..
The Fred Hutchinson Cancer Research Center


03/24/16
20160083682 

Unitary 3d culture device


A continuous device for culturing mammalian cells in a three-dimensional structure for the transplantation or implantation in vivo is described. The culturing device comprises (a) a scaffold formed by a matrix of interconnected growth surfaces spaced at regular intervals and (b) a fluid distribution means at the inlet and the exit of the growth areas.
Vivabiocell S.p.a.


03/24/16
20160083457 

Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease


The present invention relates to methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease (cd ad). In particular, the invention relates to antibodies that bind to c.
Immuron Limited


03/24/16
20160083411 

Antidiabetic enolic glucoside of phenylpyruvic acid


There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. For lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome x.
Zadec Aps


03/24/16
20160083371 

1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity


Where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.. .

03/24/16
20160083370 

Substituted heteroaryl compounds and methods of use thereof


Provided herein are novel heteroaryl compounds, pharmaceutically acceptable salts and pharmaceutical formulations thereof for selectively inhibiting serotonin reuptake and/or acting as 5-ht1a receptor agonists. Also provided herein are pharmaceutical compositions comprising the heteroaryl compounds and methods of using the pharmaceutical compositions in treating central nervous system (cns) dysfunction in a mammal, especially a human being..
Sunshine Lake Pharma Co., Ltd.


03/24/16
20160082158 

Cellular transplant site


A method of preparing a transplant site for cellular transplantation in a mammal includes the steps of inserting a foreign body comprising a biomaterial into an internal tissue; and removing the foreign body after the tissue surrounding the foreign body has undergone an inflammatory response but before significant fibrous encapsulation has occurred, leaving a neovascularized lumen suitable to receive transplanted cells or islets.. .
The Governors Of The University Of Alberta


03/24/16
20160082114 

Cytotoxic benzodiazepine derivatives


The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (i)-(vi). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent.
Immunogen, Inc.


03/24/16
20160082096 

Vaccine against streptococcal infections based on recombinant proteins


An antigenic composition comprises several antigenic components derived from antigens of streptococcus equi subsp. Equi or subsp.
Intervacc Ab


03/24/16
20160082084 

Heart failure treatment


The present invention relates to treating and/or preventing heart failure or one or more individual heart failure phenotypes in mammals using placental growth factor 2 (plgf-2).. .
Cobiores Nv


03/24/16
20160082077 

Flagellin related polypeptides and uses thereof


The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.. .
Cleveland Clinic Foundation


03/24/16
20160082052 

Agent for the anti-adhesion of skin pathogenic flora


Bacterial agents for preparing compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents being an extract of a bacterium, or a bacterium, selected for their adhesion to skin cells and anti-adhesive to pathogens of the cutaneous system.
Nestec S.a.


03/24/16
20160082040 

Nitric oxide treatment of mammary tissue


Systems, compositions, devices, and methods for treating a mammary condition in a mammal using gno delivered from a nitric oxide releasing solution (nors) are disclosed and described. In one embodiment, the mammary condition may be mastitis..
Bovicor Pharmatech Inc.


03/24/16
20160082029 

Method to enhance delivery of glutathione and atp levels in cells


A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(r,s)-d-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(r)-carboxylic acid (ribcys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the atp levels and the glutathione (gsh) levels in said tissue.. .
Max International, Llc


03/24/16
20160082017 

Estriol therapy for multiple sclerosis and other autoimmune diseases


The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..

03/24/16
20160081936 

Sustained-release formulations of colchicine and methods of using same


Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile.
Murray And Poole Enterprises Limited


03/24/16
20160081931 

Powder composition for treating a disorder in the auditory canal of mammals and use thereof


The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the ph of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats..
Pegion Operation Limited


03/24/16
20160081898 

Compositions for enhancing nail health


The present invention is directed to compositions and methods for enhancing the health of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to enhance nail health.
Allergan, Inc.


03/24/16
20160081705 

Methods and removing material from within a mammalian cavity using an insertable endoscopic instrument


An endoscope for removing tissue at a surgical site includes an elongated tubular body insertable within a mammalian cavity of a patient. An instrument channel extends between a first opening at a distal end and a second opening at a proximal end of the tubular body and is sized and configured to receive a surgical cutting assembly that includes an aspiration channel configured to remove material entering the endoscope via a distal end of the surgical cutting assembly.
Interscope, Inc.


03/24/16
20160081656 

Image guided catheters and methods of use


An interventional medical device is provided that incorporates a forward-directed ultrasound imaging system integrated into a single minimally invasive device. The medical device can be in the form of an image guided catheter having a replaceable and reusable ultrasound imaging assemble and replaceable interventional devices such as a removable introducer needle and syringe, the device having a tapered distal tip, particularly those suitable for minimally invasive direct introduction into the human or other mammalian body.

03/17/16
20160077096 

Treating patients based on immune subtypes


This document provides methods and materials for treating patients following an assessment of immune subtypes such as an assessment of peripheral blood phenotypes. For example, methods and materials for treating a mammal having a medical condition after assessing a mammal's level of cd14+/dr− cells (e.g., cd14+/dr− monocytes) and level of cd4+ cells (e.g., cd4+ t cells) and classifying the mammal has being likely to experience a favorable or unfavorable medical outcome based at least in part on the mammal's level of cd14+/dr− cells and level of cd4+ cells are provided..
Mayo Foundation For Medical Education And Research


03/17/16
20160076068 

Quantitative control of sialylation


The present disclosure is directed to the use of certain glycosyltransferase variants having n-terminal truncation deletions. Contrary to previous findings certain truncations were found to exhibit sialidase enzymatic activity, particularly a variant of human sialyltransferase (hst6gal-i) with a truncation deletion involving the first 89 n-terminal amino acids of the respective wild-type polypeptide.
Roche Diagnostics Operations, Inc.


03/17/16
20160076051 

Expression process


A process for the production of a target polypeptide is provided. The process comprises expression of an expression vector for expressing a target polypeptide in a host cell, preferably a mammalian cell, the expression vector comprising an expression cassette comprising a polynucleotide encoding a recombinant polypeptide operably linked to a fibronectin secretion leader sequence; and recovering the target polypeptide..
Fujifilm Diosynth Biotechnologies Uk Limited


03/17/16
20160075773 

Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration


The present application describes rgm a binding proteins, particularly monoclonal antibodies, and in particular cdr grafted, humanized versions thereof, which have the ability to bind to rgm a and prevent binding of rgm proteins to rgm a receptor and other rgm a binding proteins, and therefore neutralize the function of rgm a, for use in the treatment of retinal nerve fiber layer (rnfl) degeneration as well as methods of therapeutically or prophylactically treating a mammal against rnfl degeneration.. .
Abbvie Deutschland Gmbh & Co. Kg


03/17/16
20160075750 

Production of tsg-6 protein


A method of producing a protein or polypeptide, such as, for example, tsg-6 protein, or a biologically active fragment, derivative or analogue thereof, by introducing into mammalian cells a polynucleotide encoding the biologically active protein or polypeptide or biologically active fragment, derivative, or analogue thereof. The cells then are suspended in a protein-free medium that includes at least one agent that suppresses production of hyaluronic acid, hyaluronan, or a salt thereof by the cells.

03/17/16
20160075647 

Novel phenicol antibacterial agents


The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical compositions containing these novel compounds, and methods for the preparation of these compounds.. .
Zoetis Services Llc


03/17/16
20160074559 

Antimicrobial wraps for medical implants


Biodegradable antimicrobial films are provided that are solid at room temperature and substantially liquefy in situ after implantation into a mammal, such as a human patient. Methods of using the films to cover a medical device, such as a breast implant, prior to insertion into a subject are also provided..
Board Of Regents, The University Of Texas System


03/17/16
20160074533 

Vector encoding therapeutic polypeptide and safety elements to clear transduced cells


A composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) activator polynucleotide wherein the modified mammalian tmpk polynucleotide encodes a modified mammalian tmpk polypeptide that increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type mammalian tmpk polypeptide to a drug; and/or a targeting polynucleotide encoding a cell surface polypeptide that selectively binds a toxic binding agent. The disclosure also relates to use of these compositions in methods of treatment of diseases such as fabry disease..
University Health Network


03/17/16
20160074522 

Immunity inducer for saccharide antigens


The present invention provides an immunity inducer and an immunity inducing method using same. The immunity inducer has an immunopotentiation effect on any target oligosaccharide antigen, in particular oligosaccharide antigens included in mammal-derived glycoprotein n-linked sugar chains; is capable of providing a monoclonal antibody having high specificity to and affinity with target oligosaccharide antigens; and has as an effective component thereof a glycolipid including a target oligosaccharide antigen (r) and indicated by general formula (2), or a salt thereof.
National Institute Of Advanced Industrial Science And Technology


03/17/16
20160074508 

Compositions for stimulation of mammalian innate immune resistance to pathogens


Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a stir composition to the individual.. .
The Board Of Regents, The University Of Texas System


03/17/16
20160074503 

Porcine reproductive and respiratory syndrome virus compositions and uses thereof


Provided herein are embodiments relating to porcine reproductive and respiratory syndrome (prrs) virus, compositions comprising the virus, and methods of using the virus. The virus may be used to immunize a mammal, including swine.
The Board Of Trustees Of The University Of Illinois


03/17/16
20160074486 

Therapeutic composition with a botulinum neurotoxin


The present invention pertains to pharmaceutical compositions which comprise botulinum toxin from clostridium botulinum. The pharmaceutical compositions of the instant invention are not only free of a mammalian derived proteinaceous stabilizing agent but are free of any stabilizing protein..
Merz Pharma Gmbh & Co. Kgaa


03/17/16
20160074457 

Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome


Pharmaceutical/dietary supplements and food ingredient(s) derived from sphaeranthus indicus are used for controlling or treating a metabolic disorder. The supplements and food ingredient(s) are selected from sphaeranthus indicus extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof and their compositions, preferably in combination with at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from garcinia mangostana.
Laila Nutraceuticals


03/17/16
20160074431 

Methods and compositions for improving appearance and formation of scar tissue


This invention relates to methods and compositions for degrading collagen in mammalian skin, thereby improving the appearance and/or reducing the size of a closed wound, which may be a scar or a keloid and cellulite or other conditions wherein excessive collagen is a problem.. .
Johnson & Johnson Consumer Inc.


03/17/16
20160074419 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

03/17/16
20160074350 

Retinopathy treatment


A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject.. .
Chs Pharma, Inc.


03/17/16
20160074069 

Methods of selection of mammalian oocytes


The invention provides methods of selection of mammalian oocytes. In particular, the invention provides in-vitro methods of selection of viable oocytes from a population of mammalian oocytes by ranking and selecting viable oocytes..
Victoria Link Limited


03/17/16
20160073934 

Method and monitoring dynamic status of a body


Apparatus is disclosed for monitoring, measuring and/or estimating dynamic status of a body part of a vertebral mammal. The apparatus includes at least one kinematics sensor for measuring and for providing data for comparison to a first frame of reference data indicative of the dynamic status of the body part.
Dorsevi Pty Ltd.


03/17/16
20160073920 

Hybrid metal and carbon or glassy carbon mems u-ecog electrode and microelectrode structures


Microelectromechanical system are disclosed that include at least one electrode, microelectrode or combination thereof, wherein the at least one electrode comprises a carbon material, a glassy carbon material or a combination thereof. Contemplated systems are suitable for μ-ecog arrays.
San Diego State University Research Foundation (sdsurf)


03/17/16
20160073669 

Intestinal barrier integrity


The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (epa), docosahexaenoic acid (dha) and arachidonic acid (ara), and at least two distinct oligosaccharides.. .
N.v. Nutricia


03/17/16
20160073668 

Compositions and methods for increasing iron intake in a mammal


Compositions containing iron and denatured protein have been prepared that are capable of increasing serum iron and other divalent metal cations in a subject. For example, edible microbeads have been prepared containing iron entrapped within a protein matrix that provides a gastroprotective effect and improves iron bioavailability relative to previously known vehicles for delivering iron to a subject..
Solvotrin Therapeutics Limited


03/17/16
20160073616 

Method for producing chimeric animal


The method for producing a chimeric animal according to the present invention comprises introducing a mammal-derived cell into the embryo of a mammal, the cell being primed pluripotent stem cell, tissue stem cell, progenitor cell, somatic cell, or germ cell.. .

03/10/16
20160068861 

Method for detecting protein stability and uses thereof


Provided in the present invention is a genetic construct having a structure as represented by 5′-a+b+c+d+e-3′, wherein a indicates a promoter; b indicates a coding sequence of a fusion protein consisting of a target protein and a first labeled protein; c indicates a coding sequence of a connecting peptide; d indicates a coding sequence of a second labeled protein; and e indicates a terminator. Also provided in the present invention is a polypeptide having a structure as represented by b1+c1+d1, wherein b1 indicates the fusion protein consisting of the target protein and the first labelled protein; c1 indicates the connecting peptide; and d1 indicates a second labelled protein.
Shanghai Institutes For Bioligical Sciences, Chinese Academy Of Sciences


03/10/16
20160068825 

Development of protein-based biotherapeutics that penetrate cell-membrane and induce anti-cancer effect- cell-permeable glutathione peroxidase7 (cp-gpx7) in gastrointestinal track (git), polynucleotides encoding the same, and anti-cancer compositions comprising the same


Gastrointestinal track (git) including oesophageal and gastric cancers are a leading cause of cancer death worldwide. Limited therapeutic options highlight the need to understand the molecular changes responsible for the disease and to develop therapies based on this understanding.
Cellivery Therapeutics, Inc.


03/10/16
20160068812 

Method for culturing skeletal muscle for tissue engineering


The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (deta); verifying deta monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the deta monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating.
University Of Central Florida Research Foundation, Inc.


03/10/16
20160068809 

Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants


The invention relates to the use of 1-(β-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of indoleamine 2,3-dioxygenase (ido) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.. .
Idogen Ab


03/10/16
20160068467 

Amphiphilic macromolecules and methods of use thereof


Or a salt thereof, wherein a, x, y, z and r1 have any of the values defined in the specification, and methods of use thereof. For example, certain embodiments of the invention provide a method for inhibiting atherosclerosis or atherosclerotic development in a mammal, comprising administering to the mammal an effective amount of a compound of formula (i), or a pharmaceutically acceptable salt thereof..

03/10/16
20160067449 

Apparatus and methods relating to intravascular positioning of distal end of catheter


Devices and systems for navigation and positioning a central venous catheter within a patient. In an exemplary embodiment of a system of the present disclosure, the system comprises a first pole and a second pole, the first pole and the second pole configured to generate an electric field within a mammalian body sufficient to obtain a plurality of field measurements therein, and an elongated body configured for at least partial insertion into a blood vessel of the mammalian body and advancement through a vasculature, said advancement dependent upon the plurality of field measurements indicative of one or more locations of a portion of the elongated body within the vasculature.
Bard Access Systems, Inc.


03/10/16
20160067380 

Encapsulation of pancreatic cells derived from human pluripotent stem cells


The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation..
Viacyte, Inc.


03/10/16
20160067379 

Extracellular matrix for the treatment of intestinal disease and methods thereof


A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.. .
Acell, Inc.


03/10/16
20160067324 

Novel vaccine formulation for ocular immunization


The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans and animals including mammals and birds. More particularly, it relates to subunit vaccines that are effective against pathogens causing infections thereof for use in humans and animals including mammals and birds.
Medizinische UniversitÄt Wien


03/10/16
20160067292 

Bioactive apolar extract containing plant genetic material for treatment of mammalian diseases


Bioactive apolar extract of plant material containing plant genetic material to treat mammalian diseases and disorders.. .

03/10/16
20160067289 

Probiotic strains for use in treatment or prevention of osteoporosis


The present invention relates to at least one probiotic strain chosen from lactobacillus paracasei, or at least one probiotic strain chosen from lactobacillus paracaseiin combination with at least one probiotic strain chosen from lactobacillus plantarum, for use in the treatment or prevention of osteoporosis or for use in increasing the absorption of at ca2+ ions, in a mammal, preferably in a human.. .
Probi Ab


03/10/16
20160067256 

Inhibitors of hemeprotein-catalyzed lipid peroxidation


Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation.
Vanderbilt University


03/10/16
20160067214 

Method of dosing and use of soft anticholinergic esters


B) topically administering the composition to skin of an area of a mammalian subject suffering from hyperhidosis, before bedtime, such that, compared to untreated, baseline conditions, sweat production is reduced by at least about 25% for at least about six (6) hours.. .

03/03/16
20160061847 

T2r taste receptors and genes encoding same


Newly identified mammalian taste-cell-specific g protein-coupled receptors and the genes encoding said receptors are described. Specifically, t2r taste g protein-coupled receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors.
Senomyx, Inc.


03/03/16
20160061835 

Identification and characterization of a peptide affinity reagent for the detection of noroviruses in clinical samples


Embodiments of the disclosure include methods and/or compositions for the detection of viral infection, including at least norovirus infection. In particular embodiments, there are methods and/or compositions employing particular peptides and/or phage useful for detecting norovirus in a sample.
Baylor College Of Medicine


03/03/16
20160061833 

Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays


This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
Senomyx, Inc.


03/03/16
20160060660 

Biotechnological production of itaconic acid


The present invention provides a novel method and means of producing itaconic acid based on the use of the mammalian immune response gene 1 (irg1) and variants to express an enzyme which converts cis-aconitic acid to itaconic acid. The method includes cultivation a host cell comprising the igr1 gene or variants thereof and obtaining itaconic acid..
UniversitÉ Du Luxembourg


03/03/16
20160060657 

Methods and compositions for the targeted modification of a genome


Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (ltvec) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the ltvec with a crispr/cas system.
Regeneron Pharmaceuticals, Inc.


03/03/16
20160060597 

Functional myelination of neurons


Hair follicle bulge region/llp region cd34(+) mescs can be isolated from mammalian skin bearing hair follicles. These cells are multipotent and retain the ability to differentiate into cells of neural crest lineage, including glia-like cells that express the glial marker gfap, and are able to express myelin basic protein, and to remyelinate naked (unmyelinated or demyelinated) neuronal processes with a functional, dense myelin sheath.
The United States Of America As Represented By The Department Of Veterans Affairs


03/03/16
20160060314 

Development of a protein-based biotherapeutic agent that penetrates cell-membrane and induces anti-tumor effect in solid tumors - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-tumor compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060313 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-angiogenic effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-angiogenic compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060312 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-pancreatic cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-pancreatic cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060311 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-lung cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-lung cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060310 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-hepatocellular carcinoma effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-hepatocellular carcinoma compositions comprising the same


Protein transduction exploits the ability of some cell-penetrating peptide (cpp) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic cpps, named membrane translocating sequence (mts), membrane translocating motif (mtm) and macromolecule transduction domain (mtd), are able to deliver biologically active proteins into a variety of cells and tissues.
Cellivery Therapeutics, Inc.


03/03/16
20160058928 

Breast fluid expression device


Disclosed herein are biologically inspired, either manual or electronic, portable fluid expression system to be used for, but not limited to, breast milk expression from nursing women and other milk expression from any species of mammal. The fluid expression systems can be configured to mimic the anatomy of a suckling infant and the biomechanics and fluid dynamics associated with this behavior.
Mimeo Labs, Inc.


03/03/16
20160058846 

Therapeutic for treating clostridium difficile infection


The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing c. Difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing c.
London School Of Hygiene And Tropical Medicine


03/03/16
20160058837 

Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals


The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (slc) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an slc to the mammal.
The Department Of Veterans' Affairs


03/03/16
20160058832 

Medical use of syndecan-2


Sdc2, compositions that comprise sdc2, vectors encoding sdc2 and compounds that modulate expression of sdc2 by cells are used for treatment of mammalian, e.g. Human, cells to achieve immunomodulation or for other specific therapeutic interventions.
Orbsen Therapeutics Limited


03/03/16
20160058826 

Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy


The present disclosure provides methods and compositions for preventing or treating mv-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide..
Cornell University


03/03/16
20160058825 

Methods and compositions for preventing or treating ophthalmic conditions


The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pi gmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof..
Stealth Peptides International, Inc.


03/03/16
20160058795 

Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases


The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties.

03/03/16
20160058768 

Substituted amide compounds


The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .
Pfizer Inc.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.1549

4370

1 - 1 - 104